BTK and B-cell chronic lymphocytic leukemia: Approval followed the favorable findings of the TRANSCEND CLL 004 on‐going trial that evaluated R/R CLL patients who have had two lines of therapy, including BTK inhibitor, who received 100 × 106 CAR T cells and had an objective response rate of 43% and total median OS of 30.3 months.62